Exelixis
EXEL
#1695
Rank
โ‚ฌ9.48 B
Marketcap
33,21ย โ‚ฌ
Share price
0.52%
Change (1 day)
73.67%
Change (1 year)
Exelixis, Inc. is an American genomics-based drug discovery company and the producer of Cometriq, a treatment for medullary thyroid cancer.

EPS for Exelixis (EXEL)

EPS in 2023 (TTM): 0,26ย โ‚ฌ

According to Exelixis's latest financial reports the company's current EPS (TTM) is 0,27ย โ‚ฌ. In 2022 the company made an earnings per share (EPS) of 0,54ย โ‚ฌ a decrease over its 2021 EPS that were of 0,71ย โ‚ฌ.

EPS history for Exelixis from 2000 to 2023

Annual EPS

Year EPS Change
2023 (TTM)0,26ย โ‚ฌ-52.29%
20220,54ย โ‚ฌ-22.97%
20210,71ย โ‚ฌ100%
20200,35ย โ‚ฌ-65.09%
20191,01ย โ‚ฌ-53.91%
20182,19ย โ‚ฌ333.96%
20170,51ย โ‚ฌ-260.61%
2016-0,31ย โ‚ฌ-58.75%
2015-0,76ย โ‚ฌ-42.45%
2014-1,33ย โ‚ฌ5.3%
2013-1,26ย โ‚ฌ43.48%
2012-0,88ย โ‚ฌ-264.29%
20110,53ย โ‚ฌ-165.88%
2010-0,81ย โ‚ฌ-32.54%
2009-1,20ย โ‚ฌ-17.65%
2008-1,46ย โ‚ฌ75.86%
2007-0,83ย โ‚ฌ-25.64%
2006-1,12ย โ‚ฌ8.33%
2005-1,03ย โ‚ฌ-42.86%
2004-1,80ย โ‚ฌ30.34%
2003-1,38ย โ‚ฌ-5.23%
2002-1,46ย โ‚ฌ-0.65%
2001-1,47ย โ‚ฌ-51.88%
2000-3,05ย โ‚ฌ

EPS for similar companies or competitors

Company EPS EPS differencediff. Country
3,34ย โ‚ฌ 1,135.69%๐Ÿ‡ฌ๐Ÿ‡ง UK
3,03ย โ‚ฌ 1,022.57%๐Ÿ‡ซ๐Ÿ‡ท France
1,74ย โ‚ฌ 543.02%๐Ÿ‡บ๐Ÿ‡ธ USA
3,78ย โ‚ฌ 1,301.34%๐Ÿ‡บ๐Ÿ‡ธ USA
13,49ย โ‚ฌ 4,894.71%๐Ÿ‡บ๐Ÿ‡ธ USA
13,43ย โ‚ฌ 4,871.87%๐Ÿ‡บ๐Ÿ‡ธ USA
1,77ย โ‚ฌ 556.55%๐Ÿ‡บ๐Ÿ‡ธ USA
-9,53ย โ‚ฌ-3,629.83%๐Ÿ‡บ๐Ÿ‡ธ USA
-0,80ย โ‚ฌ-396.51%๐Ÿ‡บ๐Ÿ‡ธ USA